Image may be NSFW.
Clik here to view.
With $28.7 million from a recently-closed Series C round, Lumicell reported today that it plans to launch a pivotal trial of its image-guided cancer surgery tech in breast cancer.
The Wellesley, Mass.-based company added that it hopes to expand its clinical program into other solid tumor cancers, including lung, ovarian and brain cancer.
Get the full story at our sister site, Drug Delivery Business News.
The post Lumicell aims $29m Series C at pivotal breast cancer trial and expansion into other cancers appeared first on MassDevice.
